Crizotinib in ALK-positive lung cancer
Mené sur 149 patients atteints d'un cancer du poumon non à petites cellules ALK+, cet essai de phase I évalue l'efficacité et la toxicité du crizotinib
In The Lancet Oncology, Ross Camidge and colleagues report the updated results of a phase 1 trial assessing crizotinib in patients with non-small-cell lung cancer (NSCLC) and an ALK fusion. Their data confirm the efficacy of crizotinib in this subset of patients, which had previously been reported after analysis of the first 82 patients with ALK-positive disease enrolled in the trial. In the final cohort, 87 of 143 patients had an objective response (60·8%, 95% CI 52·3—68·9), with no significant difference between patients receiving different lines of treatment.1 Median progression-free survival was 9·7 months (95% CI 7·7—12·8)...
The Lancet Oncology , commentaire en libre accès, 2011